

## United States Patent and Trademark Office

CIL

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/615,589	07/08/2003	Joe S. Wilkins JR.	WRC/8c	8939
75	90 10/07/2005		EXAM	INER
Laura G. Barrow, Esq.			KRASS, FREDERICK F	
P.O. Box 215				
Estero, FL 33	928-0215	•	ART UNIT	PAPER NUMBER
			1614	

DATE MAILED: 10/07/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summan	10/615,589	WILKINS, JOE S.				
Office Action Summary	Examiner	Art Unit				
	Frederick F. Krass	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
,	action is non-final.					
<i>'</i>	, <del></del>					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-17</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
· · · · · · · · · · · · · · · · · · ·						
6) Claim(s) is/are rejected.						
· ·	7) Claim(s) is/are objected to.  8) Claim(s) <u>1-17</u> are subject to restriction and/or election requirement.					
8)⊠ Claim(s) <u>1-17</u> are subject to restriction and/or e	lection requirement.					
Application Papers		<b>(</b> .				
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
<ul><li>1. Certified copies of the priority documents have been received.</li><li>2. Certified copies of the priority documents have been received in Application No</li></ul>						
	• •	<del></del>				
3. Copies of the certified copies of the priori	•	d in this National Stage				
application from the International Bureau	• • • • • • • • • • • • • • • • • • • •	_				
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date  Notice of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Notice of Informal Patent Application (PTO-152)						
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Notice of Informal Patent Application (PTO-152)						

## **Restriction Requirement**

Restriction to one of the following inventions is required under 35 U.S.C. 121:

 Claims 1-5, drawn to methods for killing bacteria on the skin or in the nasal cavity, classified in class 422, subclass 28 plus.

- II. Claims 6-11, drawn to methods for treating psoriasis, classified in class 514, subclass886 plus.
- III. Claims 12-17, drawn to topical formulations comprising d-limonene and vitamin E oil, classified in class 514, subclass 458 plus.

Inventions III and (I or II, respectively) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product, as is self-evident from the existence of two Groups I and II, comprising two different methods of using topical compositions containing d-limonene. Additionally, the formulations of Group III are also useful for non-therapeutic applications, e.g. as lubricants.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions clearly have different modes of operation, function and effect; a method for treating bacterial infections has nothing to do with a method for treating psoriasis, a completely unrelated disorder with an inflammatory/immune etiology independent of bacterial infection.

Because these inventions are distinct/unrelated for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Moreover, because a search of each invention would not be coextensive with the other(s), and furthermore because each invention would require its own separate patentability analysis, an examination and search of these multiple inventions in a single application would constitute a serious undue burden on the examiner.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting

rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

## **Election of Species Requirement**

Should Group I be elected in response to the restriction requirement <u>supra</u>, then a further election of species requirement will be imposed as well. Group I contains claims directed to the following patentably distinct species of the claimed invention: bacterial species (*Staphyloccus aureus*, *Enterococcus faecalis*, etc.)

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/615,589

Art Unit: 1614

Applicant is advised that the reply to the 1) restriction requirement and 2) election of species

requirement (should Group I be elected in response to the first requirement) to be complete must include

an election of the invention to be examined even should the requirement be traversed (37 CFR 1.143).

A telephone call was made to Laura Barrow on 9-15-05 to request an oral election to the above

restriction requirement, but did not result in an election being made.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Frederick F. Krass whose telephone number is 571-272-0580. The examiner's schedule is

9:30AM - 6:00PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Christopher Low can be reached at 571-272-0951. The fax phone number for the organization where this

application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained from

either Private PAIR or Public PAIR. Status information for unpublished applications is available through

Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC)

at 866-217-9197 (toll-free).

Frederick Krass Primary Examiner

Art Unit 16

Page 5